IL-17 (IL-17A) polyclonal, anti-human
€0.00
In stock
SKU
AC-ABG10218
Catalog Number: AC-ABG10218
Size(s): 50 µg, 100 µg
Host: Rabbit
Applications: WB, IHC, E
Datasheet
Request Information
Size(s): 50 µg, 100 µg
Host: Rabbit
Applications: WB, IHC, E
Datasheet
Request Information
Source:
Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIL-17A. Anti-Human IL-17A specific antibody was purified by affinity chromatography employing immobilized hIL-17 matrix.
Western Blot:
To detect hIL-17A by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-17A is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Sandwich ELISA:
To detect hIL-17A by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems Biotinylated Anti-Human IL-17A (60-017ABT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-17A.
Immunohistochemistry:
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 0.25 µg/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended. Optimal concentrations and conditions may vary.
Neutralization:
To yield one-half maximal inhibition [ND50] of the biological activity of hIL-17A (50.0 ng/ml), a concentration of 0.9-1.3 μg/ml of this antibody is required.
Formulation: A sterile filtered antibody solution was lyophilized from PBS, pH 7.2.
Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hIL-17A. Anti-Human IL-17A specific antibody was purified by affinity chromatography employing immobilized hIL-17 matrix.
Western Blot:
To detect hIL-17A by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-17A is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Sandwich ELISA:
To detect hIL-17A by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems Biotinylated Anti-Human IL-17A (60-017ABT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hIL-17A.
Immunohistochemistry:
This antibody stained formalin-fixed, paraffin-embedded sections of human breast invasive ductal carcinoma. The recommended concentration is 0.25 µg/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended. Optimal concentrations and conditions may vary.
Neutralization:
To yield one-half maximal inhibition [ND50] of the biological activity of hIL-17A (50.0 ng/ml), a concentration of 0.9-1.3 μg/ml of this antibody is required.
Formulation: A sterile filtered antibody solution was lyophilized from PBS, pH 7.2.
Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.
| Is Featured? | No |
|---|
Write Your Own Review